Statins may act through increasing tissue plasminogen activator/plasmin activity to lower risk of Alzheimer's disease

CNS Spectrums

Volumn 14, Issue 5, 2009, Pages 234-235

  Tsai, Shih Jen ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; BRAIN DERIVED NEUROTROPHIC FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLASMIN; TISSUE PLASMINOGEN ACTIVATOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (40 42); AMYLOID BETA-PROTEIN (40-42); APOLIPOPROTEIN E; BRAIN DERIVED NEUROTROPHIC FACTOR PRECURSOR; BRAIN-DERIVED NEUROTROPHIC FACTOR PRECURSOR; PEPTIDE FRAGMENT; PROTEIN PRECURSOR;

ALZHEIMER DISEASE; CELL SURVIVAL; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERCHOLESTEROLEMIA; LETTER; NERVE CELL NECROSIS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FUNCTION; RISK REDUCTION; ANIMAL; ARTICLE; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APOLIPOPROTEINS E; BRAIN-DERIVED NEUROTROPHIC FACTOR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PEPTIDE FRAGMENTS; PLASMIN; PROTEIN PRECURSORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 67649882745     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900025360     Document Type: Letter

References (17)

1. Rockwood K. Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. Acta Neurol Scand Suppl. 2006;185:71-77. (Pubitemid 44015228)
2. Crisby M, Carlson LA, Winblad B. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord. 2002;16:131-136. (Pubitemid 35001087)
3. Sparks DL, Sabbagh M, Connor D, et al. Statin therapy in Alzheimer's disease. Acta Neurol Scand Suppl. 2006;185:78-86.
4. Ledesma MD, Dotti CG. The conflicting role of brain cholesterol in Alzheimer's disease: lessons from the brain plasminogen system. Biochem Soc Symp. 2005;72:129-138
5. Friedhoff LT, Cullen EI, Geoghagen NS, Buxbaum JD. Treatment with controlled- release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. Int J Neuropsychopharmacol. 2001;4:127-130.
6. Melchor JP, Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost. 2005;93:655-660. (Pubitemid 40485400)
7. Essig M, Vrtovsnik F, Nguyen G, Sraer JD, Friedlander G. Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins. J Am Soc Nephrol. 1998;9:1377-1388. (Pubitemid 28354547)
8. Lopez S, Peiretti F, Bonardo B, Juhan-Vague I, Nalbone G. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis. 2000;152:359-366. (Pubitemid 30686323)
9. Mussoni L, Banfi C, Sironi L, Arpaia M, Tremoli E. Fluvastatin inhibits basal and stimu lated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells. Thromb Haemost. 2000;84:59-64. (Pubitemid 30433669)
10. Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep. 2000;1:530-535.
11. Ledesma MD, Abad-Rodriguez J, Galvan C, et al. Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains. EMBO Rep. 2003;4:1190-1196. (Pubitemid 38088415)
12. Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol. 2001;63:71-124. (Pubitemid 30752602)
13. Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med. In press.
14. Pang PT, Teng HK, Zaitsev E, et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science. 2004;306:487-491. (Pubitemid 39372449)
15. Barnes P, Thomas KL. Proteolysis of proBDNF is a key regulator in the formation of memory. PLoS ONE. 2008;3:e3248.
16. Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat Rev Neurosci. 2005;6:603-614.
17. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923. (Pubitemid 23275809)